Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02074410 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease
A Phase 2 study, sponsored by Omeros Corporation.
- Terminated
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
NCT02074410 is a Phase 2 study that was terminated before completion, run by Omeros Corporation. The registered enrollment target is 22 participants.
The verdict
NCT02074410, a Phase 2 study, was terminated before completion, sponsored by Omeros Corporation.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability and pharmacokinetics of OMS643762 (the study drug) in subjects with Huntington's disease (HD).
Interventions
- DRUG Placebo
- DRUG OMS643762
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-10-15 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02074410
The ClinicalTrials.gov registry entry for NCT02074410 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Omeros Corporation, which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02074410 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02074410 about?
NCT02074410 is a clinical study titled "Safety and Efficacy of OMS643762 in Subjects With Huntington's Disease". The purpose of this study is to determine the safety, tolerability and pharmacokinetics of OMS643762 (the study drug) in subjects with Huntington's disease (HD).
What is the current status of trial NCT02074410?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2014-01. Estimated completion is 2014-10-15.
What interventions are being tested in trial NCT02074410?
The interventions under investigation include: Placebo (DRUG), OMS643762 (DRUG).
Who is sponsoring clinical trial NCT02074410?
This trial is sponsored by Omeros Corporation, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.